Alrehaili Amani A, Gharib Amal F, Bakhuraysah Maha M, Alharthi Afaf, Alsalmi Ohud, Alsaeedi Fouzeyyah Ali, Alhakami Reem Ali, Alasmari Kamilah Ali, Mohammed Nuha, Elsawy Wael H
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Laboratory and Blood Bank, King Faisal Medical Complex, Ministry of Health, Taif 26524, Saudi Arabia.
Diseases. 2024 Mar 11;12(3):55. doi: 10.3390/diseases12030055.
Squamous cell carcinoma of the head and neck (HNSCC) is a globally prevalent form of cancer with significant morbidity and mortality rates. The present study examines the relationship of serum pro-inflammatory cytokines and leptin levels with the effectiveness of therapy in individuals with HNSCC and their potential role as biomarkers for treatment response and toxicity. Induction chemotherapy and concomitant chemoradiotherapy were evaluated for efficacy and safety in 52 individuals with HNSCC. Both response and toxicity were evaluated, and serum levels of pro-inflammatory cytokines Interlukin-1 beta (IL-1β), Interlukin-2 (IL-2), Interlukin-6 (IL-6), and Tumor Necrosis Factor-Alpha (TNF-α) and leptin were measured using enzyme-linked immunoassay before and after treatment. Before treatment, these measurements were made in comparison with a control group with 50 healthy people. The results showed that serum cytokines and leptin levels varied depending on the response to treatment, with patients who had a complete or partial response (PR) showing significant decreases in IL-1 β, IL-6, and TNF-α levels and significant increases in IL-2 and leptin levels after treatment, with an improvement in cachexia. These results imply that variations in serum pro-inflammatory cytokines and leptin levels are likely related to the therapeutic effectiveness in HNSCC and may act as biomarkers for treatment response.
头颈部鳞状细胞癌（HNSCC）是一种在全球普遍存在的癌症形式，具有较高的发病率和死亡率。本研究探讨血清促炎细胞因子和瘦素水平与HNSCC患者治疗效果之间的关系，以及它们作为治疗反应和毒性生物标志物的潜在作用。对52例HNSCC患者的诱导化疗和同步放化疗的疗效和安全性进行了评估。评估了反应和毒性，并在治疗前后使用酶联免疫吸附测定法测量血清促炎细胞因子白细胞介素-1β（IL-1β）、白细胞介素-2（IL-2）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）和瘦素的水平。在治疗前，将这些测量结果与50名健康人的对照组进行比较。结果显示，血清细胞因子和瘦素水平因治疗反应而异，完全或部分缓解（PR）的患者在治疗后IL-1β、IL-6和TNF-α水平显著降低，IL-2和瘦素水平显著升高，恶病质有所改善。这些结果表明，血清促炎细胞因子和瘦素水平的变化可能与HNSCC的治疗效果有关，并可能作为治疗反应的生物标志物。
